Qritive: Difference between revisions
Created page with "{{Infobox Startup |logo=Qritive-logo.png |status=Active |website=https://www.qritive.com/ |vertical=Medtech, Artificial intelligence, Digital Health |trl=Deployment (TRL 7-8) |latest_funding=Series A |founding_year=2017 |headquarters=Singapore }} {{PAGENAME}} is a COUNTRY-based startup developing TECHNOLOGY for APPLICATION. ==Technology== Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key di..." |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 9: | Line 9: | ||
|headquarters=Singapore | |headquarters=Singapore | ||
}} | }} | ||
{{PAGENAME}} is a | {{PAGENAME}} is a Singapore-based startup developing [[medical ai]] to provide clinical decision support for interpretations of pathology whole slide image scans. | ||
==Technology== | ==Technology== | ||
Qritive offers a suite of AI-powered diagnostic modules designed to support pathologists across a broad range of clinical applications—from cancer diagnosis and metastasis detection on Hematoxylin and Eosin stained whole-slide images to biomarker analysis on immunohistochemistry whole-slide images. Their modules are able to analyse entire whole-slide images within seconds<ref>{{Cite web |title=Other AI Modules |url=https://www.qritive.com/other-ai-modules |access-date=2025-12-26 |website=Qritive |language=en}}</ref>. | |||
Qritive has developed a comprehensive image management system to streamline pathology workflows from slide viewing and case management to AI-supported diagnosis and structured reporting<ref>{{Cite web |title=Pantheon ™ |url=https://www.qritive.com/pantheon |access-date=2025-12-26 |website=Qritive |language=en}}</ref>. | |||
==Traction== | ==Traction== | ||
The startup's diagnostic solution to support detection and grading of prostate cancer was given Class C In Vitro Diagnostic (IVD) Approval from Singapore’s Health Sciences Authority in August 2025<ref>{{Cite web |last=Qritive |date=2025-08-05 |title=QAi Prostate Grade Receives Class C IVD Approval from Singapore’s Health Sciences Authority |url=https://www.qritive.com/post/qai-prostate-grade-receives-class-c-ivd-approval-from-singapore-s-health-sciences-authority |access-date=2025-12-26 |website=Qritive |language=en}}</ref> and regulatory approval from Abu Dhabi's Department of Health in July 2025<ref>{{Cite web |last=Qritive |date=2025-07-28 |title=QAi Prostate Grade Receives Regulatory Approval from Abu Dhabi’s Department of Health |url=https://www.qritive.com/post/qai-prostate-grade-receives-regulatory-approval-from-abu-dhabi-s-department-of-health |access-date=2025-12-26 |website=Qritive |language=en}}</ref>. | |||
In August 2025, Qritive announced that their lymph node metastasis detection solution would be adopted by Dr Lal PathLabs, an Indian diagnostic provider<ref>{{Cite web |last=Qritive |date=2025-08-20 |title=Dr Lal PathLabs Selects Qritive’s AI-Powered Solution to Strengthen Cancer Diagnostics |url=https://www.qritive.com/post/dr-lal-pathlabs-selects-qritives-ai-powered-solution-to-strengthen-cancer-diagnostics |access-date=2025-12-26 |website=Qritive |language=en}}</ref>. | |||
In September 2024, the startup announced a collaboration with Roche, to integrate their solution into Roche's digital pathology platform<ref>{{Cite web |last=Qritive |date=2024-09-11 |title=Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI |url=https://www.qritive.com/post/qritive-joins-forces-with-roche-to-redefine-global-cancer-diagnostics-with-ai |access-date=2025-12-26 |website=Qritive |language=en}}</ref>. | |||
==Accolades== | ==Accolades== | ||
In July 2025, the startup was selected as an awardee at the Japan Smart Healthy Aging QuickFire Challenge, an initiative by Johnson & Johnson Innovation to support breakthrough healthcare solutions focused on increasing healthy life expectancy in Japan<ref>{{Cite web |last=Qritive |date=2025-06-30 |title=Qritive Recognized in Japan Smart Healthy Aging QuickFire Challenge |url=https://www.qritive.com/post/qritive-recognized-in-japan-smart-healthy-aging-quickfire-challenge |access-date=2025-12-26 |website=Qritive |language=en}}</ref>. | |||
==Funding== | ==Funding== | ||
Qritive raised a $7.5 million Series A round led by [[MassMutual Ventures]] in January 2023<ref>{{Cite web |date=2023-01-09 |title=Healthcare AI Firm Qritive Raises $7.5M to Expand into New Markets |url=https://apnews.com/press-release/ein-presswire-newsmatics/business-medical-technology-singapore-ein-presswire-newsmatics-boston-0a6efe37a84d2126137b725f5790f30e |access-date=2025-12-26 |website=AP News |language=en}}</ref>.{{Startup/Funding history}} | |||
== | |||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 01:47, 26 December 2025
 | |
| Status | Active |
|---|---|
| Website | https://www.qritive.com/ |
| Vertical(s) | Medtech, Artificial intelligence, Digital Health |
| Latest Funding Round | Series A |
| Year founded | 2017 |
| Headquarters | Singapore |
| Technology Readiness Level | Deployment (TRL 7-8) |
Qritive is a Singapore-based startup developing medical ai to provide clinical decision support for interpretations of pathology whole slide image scans.
Technology
Qritive offers a suite of AI-powered diagnostic modules designed to support pathologists across a broad range of clinical applications—from cancer diagnosis and metastasis detection on Hematoxylin and Eosin stained whole-slide images to biomarker analysis on immunohistochemistry whole-slide images. Their modules are able to analyse entire whole-slide images within seconds[1].
Qritive has developed a comprehensive image management system to streamline pathology workflows from slide viewing and case management to AI-supported diagnosis and structured reporting[2].
Traction
The startup's diagnostic solution to support detection and grading of prostate cancer was given Class C In Vitro Diagnostic (IVD) Approval from Singapore’s Health Sciences Authority in August 2025[3] and regulatory approval from Abu Dhabi's Department of Health in July 2025[4].
In August 2025, Qritive announced that their lymph node metastasis detection solution would be adopted by Dr Lal PathLabs, an Indian diagnostic provider[5].
In September 2024, the startup announced a collaboration with Roche, to integrate their solution into Roche's digital pathology platform[6].
Accolades
In July 2025, the startup was selected as an awardee at the Japan Smart Healthy Aging QuickFire Challenge, an initiative by Johnson & Johnson Innovation to support breakthrough healthcare solutions focused on increasing healthy life expectancy in Japan[7].
Funding
Qritive raised a $7.5 million Series A round led by MassMutual Ventures in January 2023[8].
| Funding History | |
|---|---|
| Investor | Round |
| MassMutual Ventures | Series A |
| Seeds Capital | Series A |
| Exfinity Venture Partners | Series A |
Note: This list is community-maintained and may be incomplete or contain inaccuracies.
References
- ↑ "Other AI Modules". Qritive. Retrieved 2025-12-26.
- ↑ "Pantheon ™". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-08-05). "QAi Prostate Grade Receives Class C IVD Approval from Singapore's Health Sciences Authority". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-07-28). "QAi Prostate Grade Receives Regulatory Approval from Abu Dhabi's Department of Health". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-08-20). "Dr Lal PathLabs Selects Qritive's AI-Powered Solution to Strengthen Cancer Diagnostics". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2024-09-11). "Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-06-30). "Qritive Recognized in Japan Smart Healthy Aging QuickFire Challenge". Qritive. Retrieved 2025-12-26.
- ↑ "Healthcare AI Firm Qritive Raises $7.5M to Expand into New Markets". AP News. 2023-01-09. Retrieved 2025-12-26.